AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03593005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT05997173 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Investigation of scale of control
Study NCT05997173 — intervention group
Intervention type: OTHER
Intervention: Non erosive OLP
Description: Investigation of cale of non erosive OLP patients
Study NCT05997173 — intervention group
Intervention type: OTHER
Intervention: Erosive OLP
Description: Investigation of cale of erosive OLP patients
Study NCT01875874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Description: Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Given IV
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-coli L-asparaginase
Description: Given IM or IV
Study NCT01201824 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intracavitary ultrasound
Description: intracavitary ultrasound done during surgical intervention
Study NCT02973295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Capsules contains 100 mg of silymarin
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO
Study NCT02973295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule will be identical in shape, size and color, packed in the same way like verum
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, PO or IT
Study NCT01091038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Clinical Decision Support
Description: The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
Study NCT01091038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Routine Care
Study NCT02520544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade stem
Description: Total hip replacement
Study NCT02520544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade II stem
Description: Total hip replacement
Study NCT02520544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident/Tritanium cup
Description: Total hip replacement
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT
Study NCT04483193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
Study NCT01421238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, IT or SC
Study NCT03286634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT02057640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20mg, on day 1, 3, 5, 15, 17, 19, 28
Study NCT02057640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg, on day 1, 2, 8, 9, 15, 16, 28
Study NCT02057640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: 4mg on day 1, 8, 15, 28
Study NCT02374788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer intervention
Description: Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
Study NCT02374788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group meetings
Description: Participants receive 12 group meetings over two years' time.
Study NCT02374788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual consultations
Description: Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
Study NCT03709069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Albumin supplementation
Description: Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
Study NCT03687294 — intervention group
Intervention type: DEVICE
Intervention: enzyme linked immunosorbent assay (ELISA)
Description: ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Study NCT00003566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videothoracoscopy
Study NCT03076489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Visit
Description: blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
Study NCT03076489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-line questionnaires
Description: The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
Study NCT03076489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
Study NCT01904396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Study NCT03604172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
Study NCT03604172 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
Study NCT03993886 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CorBand
Description: The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
Study NCT03993886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Activity Monitor
Description: commercially available accelerometer to be worn on wrist
Study NCT03993886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bioimpedance spectrometer
Description: Commercially available bioimpedance monitor.
Study NCT03993886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ECG
Description: Commercially available electrocardiogram machine
Study NCT03993886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: respiratory rate sensor
Description: Commercially available respiratory rate sensor.
Study NCT04166370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
Study NCT04166370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened (Services and SBCC)
Description: Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior.
Study NCT04166370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened (Services and SBCC) + CCT
Description: Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
Study NCT05131334 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: auriStim, for auricular vagal stimulation
Description: For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
Study NCT03073811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enhanced nutrition intervention
Description: Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
Study NCT03073811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
Study NCT03931850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
Study NCT03931850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal nerve block
Description: Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
Study NCT03192293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Simvastatin/Fulvestrant
Description: 7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans
Study NCT00118248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT03459469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: This is an Investigational drug
Study NCT04222699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment, 2%
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
Study NCT04222699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Chlorhexidine, 4%
Description: Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury.
Study NCT00700882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study NCT04166578 — intervention group
Intervention type: DRUG
Intervention: lignocaine
Description: The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
Study NCT04166578 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsyfication
Description: Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
Study NCT04166578 — intervention group
Intervention type: PROCEDURE
Intervention: Intraocular lens implantation
Description: An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
Study NCT04166578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Visual Analog Scale for Pain
Description: VAS for Pain is a new tool developed to assess the pain in quantitative terms.
Study NCT04166578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Brief Pain Inventory-short form
Description: BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
Study NCT04166578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Best corrected visual acuity measurment
Description: Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
Study NCT04166578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Slit-lamp biomicroscopy
Description: Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
Study NCT02901249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Study NCT02901249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study NCT01263470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
Study NCT04683952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training with Humified High Flow Nasal Cannula
Description: The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
Study NCT04683952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training - Control Group
Description: The control group will perform exercise training in spontaneous breathing.
Study NCT02913092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic sensor and OW education
Description: MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
Study NCT00056316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training: Experimental
Description: Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
Study NCT03504475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Tablet 20 mg
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
Study NCT03504475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil® 20 mg
Description: Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
Study NCT02820753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR + (Text or Portal)
Description: Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey.
Study NCT02290301 — intervention group
Intervention type: DRUG
Intervention: gemigliptin
Study NCT03168581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
Study NCT02345629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cordotomy
Description: Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
Study NCT02345629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cordotomy
Description: Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.